Anapharm Bioanalytics is a customer-focused bioanalytical CRO specialized in small and large molecule bioanalysis. Led by a team with over 30 years’ experience in method development, validation and sample analysis, we support drug development programs for the pharmaceutical, biotechnological and generic industries worldwide. Equipped with state-of-the-art LC-MS/MS and LBA technology platforms, Anapharm Bioanalytics provides an array of services including PK studies, biomarker testing and immunogenicity assays throughout preclinical and clinical stages. Our global network of partners allows us to provide full-service outsourcing solutions to conduct preclinical, Phase I-IV clinical trials, and bioequivalence studies for international registration. Our clients benefit from a deep scientific expertise combined with a robust quality system. All our activities are compliant with GLP and GCP, having undergone 20+ regulatory inspections by the FDA, several EU Health Authorities and ANVISA (Brazil). Whether your drug candidate is a new chemical entity, a new biologic, a generic or a biosimilar, do not hesitate to contact us at info@anapharmbioanalytics.com.
Looking for a particular Anapharm Bioanalytics employee's phone or email?
The Anapharm Bioanalytics annual revenue was $16.2 million in 2026.
Javier Torres Caturla is the CEO of Anapharm Bioanalytics.
56 people are employed at Anapharm Bioanalytics.
Anapharm Bioanalytics is based in Barcelona, Catalonia.
The NAICS codes for Anapharm Bioanalytics are [54, 5417, 541].
The SIC codes for Anapharm Bioanalytics are [873, 87].